AAPL 212.78 -1.1429% MSFT 386.0 -0.4693% NVDA 118.159 0.5437% GOOGL 162.26 -0.9946% GOOG 164.29 -1.1968% AMZN 194.215 -0.6776% META 590.9 1.1711% AVGO 189.5096 -3.0988% LLY 839.62 0.3118% TSLA 233.08 -1.1787% TSM 177.34 2.0603% V 339.53 -0.1% JPM 239.365 0.1066% UNH 510.88 1.5262% NVO 78.63 -0.4684% WMT 85.915 -0.4807% LVMUY 130.5 -2.1152% XOM 115.85 0.3812% LVMHF 655.0 -2.1687% MA 536.55 0.0858%
Last update at 2024-11-21T21:07:48.198069Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -65.62100M | -71.71500M | -63.16200M | -64.16700M | -48.26200M |
| Minority interest | - | - | - | - | - |
| Net income | -65.38100M | -71.47200M | -62.93400M | -64.06800M | -48.15300M |
| Selling general administrative | 8.57M | 32.32M | 6.54M | 9.81M | 7.44M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 27.68M | 14.35M | 16.84M | 16.12M | 12.46M |
| Reconciled depreciation | 10.48M | 9.85M | 9.75M | 9.72M | 4.27M |
| Ebit | -47.04700M | -58.03900M | -45.16400M | -55.12600M | -43.61800M |
| Ebitda | -43.95300M | -52.38200M | -43.23000M | -47.34900M | -42.63100M |
| Depreciation and amortization | - | - | - | - | - |
| Non operating income net other | - | - | - | - | - |
| Operating income | -46.75100M | -62.64500M | -46.38200M | -55.34500M | -46.80100M |
| Other operating expenses | - | 3.24M | 3.24M | 3.24M | 3.24M |
| Interest expense | 11.19M | 9.32M | 10.18M | 7.10M | 1.36M |
| Tax provision | -0.24000M | -0.24300M | -0.22800M | -0.09900M | -0.10900M |
| Interest income | - | 0.08M | - | - | - |
| Net interest income | -17.69000M | -8.41100M | -15.76800M | -7.93400M | -1.40200M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.24000M | -0.24300M | -0.22800M | -0.09900M | -0.10900M |
| Total revenue | 57.48M | 48.27M | 43.13M | 37.44M | 27.81M |
| Total operating expenses | 104.23M | 110.91M | 89.51M | 92.79M | 74.61M |
| Cost of revenue | 29.80M | 33.92M | 26.28M | 21.33M | 15.35M |
| Total other income expense net | - | - | - | - | - |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -65.38100M | -71.47200M | -62.93400M | -64.06800M | -48.15300M |
| Net income applicable to common shares | -47.68100M | -71.47200M | -62.93400M | -64.06800M | -48.15300M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 114.28M | 142.48M | 210.52M | 268.32M | 139.38M |
| Intangible assets | 4.77M | 5.07M | 5.64M | 6.29M | 6.58M |
| Earning assets | - | - | - | - | - |
| Other current assets | 5.97M | 2.15M | 1.69M | 1.42M | 1.46M |
| Total liab | 144.56M | 176.38M | 173.69M | 183.84M | 52.03M |
| Total stockholder equity | -30.28400M | -33.89700M | 36.82M | 84.48M | 87.35M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 10.11M | 1.86M | 1.32M | 1.59M | 3.01M |
| Common stock | -220.30200M | 0.57M | 0.57M | 0.56M | 0.51M |
| Capital stock | -220.30200M | -220.65700M | -220.65700M | -220.66800M | -220.71800M |
| Retained earnings | -425.66300M | -526.40500M | -455.34300M | -392.25900M | -328.07800M |
| Other liab | 0.35M | 0.39M | 0.36M | 0.51M | 1.53M |
| Good will | - | - | - | - | - |
| Other assets | 5.51M | 2.75M | 1.90M | 1.62M | 6.58M |
| Cash | 24.93M | 52.32M | 122.47M | 177.53M | 62.34M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 42.45M | 33.70M | 29.45M | 23.18M | 20.28M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 82.78M | 81.83M | 2.85M | - | - |
| Short term debt | - | - | - | - | - |
| Short long term debt | 15.00M | 6.00M | 0.06M | 0.12M | 1.32M |
| Short long term debt total | - | - | - | - | - |
| Other stockholder equity | 1.66M | -219.94100M | -220.28200M | -221.85400M | -217.85400M |
| Property plant equipment | 31.53M | 37.19M | 40.10M | 43.42M | 30.39M |
| Total current assets | 69.93M | 95.13M | 159.98M | 214.63M | 90.78M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | -30.50100M | -38.96400M | 31.18M | 78.19M | 80.77M |
| Short term investments | - | - | - | - | - |
| Net receivables | 18.93M | 23.35M | 18.91M | 20.32M | 13.86M |
| Long term debt | 92.71M | 128.15M | 125.26M | 136.22M | 16.45M |
| Inventory | 18.91M | 16.11M | 15.71M | 14.16M | 11.92M |
| Accounts payable | 11.75M | 11.56M | 13.91M | 9.07M | 7.97M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.20M | 0.02M | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 44.34M | 47.35M | 50.53M | 53.70M | 48.60M |
| Capital lease obligations | 14.65M | 20.01M | 25.24M | 30.24M | 17.56M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -1.00000M | -1.00000M | -1.00000M | -2.98900M | -2.98900M |
| Change to liabilities | -0.13900M | -0.99500M | 5.92M | 0.55M | 3.12M |
| Total cashflows from investing activities | -5.43100M | -3.74800M | -4.00700M | -5.49600M | -5.82000M |
| Net borrowings | -0.51900M | -1.08900M | -7.16700M | 121.70M | -3.58000M |
| Total cash from financing activities | 22.46M | -1.20400M | -11.52300M | 175.02M | -1.50700M |
| Change to operating activities | - | - | - | - | - |
| Net income | -47.68100M | -71.47200M | -62.93400M | -64.06800M | -48.15300M |
| Change in cash | -27.39700M | -70.14600M | -55.05700M | 115.19M | -49.22600M |
| Begin period cash flow | 53.52M | 123.67M | 178.72M | 63.54M | 112.77M |
| End period cash flow | 26.12M | 53.52M | 123.67M | 178.72M | 63.54M |
| Total cash from operating activities | -44.85500M | -65.71600M | -39.26700M | -54.25400M | -41.99300M |
| Issuance of capital stock | 23.05M | - | 0.00000M | 53.36M | 2.10M |
| Depreciation | 10.48M | 9.78M | 9.66M | 9.61M | 4.43M |
| Other cashflows from investing activities | -2.49400M | 0.00700M | 0.01M | 0.00800M | 0.00800M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -5.29700M | -2.73700M | -4.04200M | -3.85800M | -2.85900M |
| Change to account receivables | 1.58M | -5.91600M | 1.45M | -1.18200M | -4.06000M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | -2.12600M | -0.11500M | -4.35600M | -2.34800M | -0.02900M |
| Change to netincome | -3.79800M | 5.56M | 10.59M | 4.59M | 5.38M |
| Capital expenditures | 1.57M | 3.69M | 3.00M | 2.12M | 5.57M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -3.85700M | -9.64800M | 3.33M | -4.49300M | -3.79700M |
| Stock based compensation | 0.64M | 0.76M | 1.43M | 1.23M | - |
| Other non cash items | 17.61M | 8.25M | 15.69M | 7.97M | 1.38M |
| Free cash flow | -46.79200M | -69.47100M | -42.28700M | -56.76900M | -47.82100M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BIOGF Biocartis Group NV |
- -% | - | - | - | 1.08 | - | 2.80 | -4.0767 |
| TMO Thermo Fisher Scientific Inc |
-0.73 0.14% | 517.68 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-0.275 0.13% | 209.99 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| A Agilent Technologies Inc |
-2.24 1.83% | 119.97 | 34.36 | 26.39 | 6.59 | 7.14 | 6.78 | 23.56 |
| IDXX IDEXX Laboratories Inc |
-1.5 0.36% | 420.65 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.
Generaal de Wittelaan 11 B, Mechelen, Belgium, 2800
| Name | Title | Year Born |
|---|---|---|
| Mr. Herman Verrelst | CEO & Exec. Director | 1974 |
| Mr. Jean-Marc Roelandt | Chief Financial Officer | 1965 |
| Mr. Piet Houwen | Chief Operating Officer | 1968 |
| Mr. Benoit Devogelaere | Chief Technology Officer | 1981 |
| Mr. Geert Maertens Ph.D. | Chairman of Scientific Advisory Board & Chief Scientific Officer | NA |
| Renate Degrave | Head of IR & Corp. Communications | NA |
| Ms. Susy Spruyt | Head of People & Organization | 1968 |
| Dr. Erwin Sablon | Head of R&D and Alliance Management | 1965 |
| Mr. Reginald Van Genechten | Head of Manufacturing & Supply Chain | 1966 |
| Mr. Dirk Zimmermann | Global Head of Pharma Collaborations & Partnering | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...